The Mortality of Colistin Monotherapy vs. Colistin-Sulbactam for Carbapenem-Resistant Acinetobacter baumannii Pneumonia: A Propensity Score Analysis.

IF 2.9 Q2 INFECTIOUS DISEASES
Nadia Cheh-Oh, Chutchawan Ungthammakhun, Dhitiwat Changpradub, Wichai Santimaleeworagun
{"title":"The Mortality of Colistin Monotherapy <i>vs.</i> Colistin-Sulbactam for Carbapenem-Resistant <i>Acinetobacter baumannii</i> Pneumonia: A Propensity Score Analysis.","authors":"Nadia Cheh-Oh, Chutchawan Ungthammakhun, Dhitiwat Changpradub, Wichai Santimaleeworagun","doi":"10.3947/ic.2024.0125","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study compared the mortality rates within 30 days of 2 different doses of sulbactam (6 g and 9-12 g daily) when used in colistin (COL)-based treatment regimens and COL monotherapy for carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB).</p><p><strong>Materials and methods: </strong>This retrospective cohort study included 234 participants diagnosed with severe pneumonia due to CRAB infection at Phramongkutklao Hospital, Thailand, from July 1, 2011, to April 30, 2023. Participants were categorized into three groups: COL monotherapy, COL with 6 g of sulbactam daily (COL+S6g), and COL with 9-12 g of sulbactam daily (COL+SHD). Following the exclusion of patients with renal impairment (serum creatinine ≥1.5 mg/dl), a 1:2 propensity score (PS) matching was used to ensure comparable groups, with the COL group designated as the control. The matching variables included age, APACHE II scores, serum creatinine, intensive care units admission, and bacteremia. The number of participants in each group was as follows: 19 in COL, 32 in COL+S6g, and 38 in COL+SHD. The primary outcomes assessed were all-cause mortality rates at 7, 14, and 30 days. Kaplan-Meier survival curves and the Log-rank test were used to evaluate differences between groups, while multivariate Cox regression models were applied to determine the impact of treatment regimens.</p><p><strong>Results: </strong>The unmatching PS analysis indicated that the COL+SHD regimen significantly reduces mortality compared to the COL regimen; hazard ratios (HR) were 0.18 (95% confidence interval [CI], 0.06-0.55) for 7-day mortality and 0.53 (95% CI,-0.29-0.97) for 30-day mortality. In addition, the COL+SHD regimen also lowered mortality more than the COL+S6g regimen within 7 days (HR, 0.29; 95% CI, 0.11-0.75). After PS matching, the COL+SHD regimen significantly reduced 7-day mortality compared to the COL regimen (adjusted HR, 0.24; 95% CI, -0.07-0.82). However, COL+S6g did not differ in mortality from either COL+SHD or COL for 7-day mortality. At 14 days and 30 days, there were no significant regimens to reduce mortality.</p><p><strong>Conclusion: </strong>Combining COL+SHD effectively reduced death in 7 days from severe pneumonia in CRAB infection treatment.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"138-147"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972904/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2024.0125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study compared the mortality rates within 30 days of 2 different doses of sulbactam (6 g and 9-12 g daily) when used in colistin (COL)-based treatment regimens and COL monotherapy for carbapenem-resistant Acinetobacter baumannii (CRAB).

Materials and methods: This retrospective cohort study included 234 participants diagnosed with severe pneumonia due to CRAB infection at Phramongkutklao Hospital, Thailand, from July 1, 2011, to April 30, 2023. Participants were categorized into three groups: COL monotherapy, COL with 6 g of sulbactam daily (COL+S6g), and COL with 9-12 g of sulbactam daily (COL+SHD). Following the exclusion of patients with renal impairment (serum creatinine ≥1.5 mg/dl), a 1:2 propensity score (PS) matching was used to ensure comparable groups, with the COL group designated as the control. The matching variables included age, APACHE II scores, serum creatinine, intensive care units admission, and bacteremia. The number of participants in each group was as follows: 19 in COL, 32 in COL+S6g, and 38 in COL+SHD. The primary outcomes assessed were all-cause mortality rates at 7, 14, and 30 days. Kaplan-Meier survival curves and the Log-rank test were used to evaluate differences between groups, while multivariate Cox regression models were applied to determine the impact of treatment regimens.

Results: The unmatching PS analysis indicated that the COL+SHD regimen significantly reduces mortality compared to the COL regimen; hazard ratios (HR) were 0.18 (95% confidence interval [CI], 0.06-0.55) for 7-day mortality and 0.53 (95% CI,-0.29-0.97) for 30-day mortality. In addition, the COL+SHD regimen also lowered mortality more than the COL+S6g regimen within 7 days (HR, 0.29; 95% CI, 0.11-0.75). After PS matching, the COL+SHD regimen significantly reduced 7-day mortality compared to the COL regimen (adjusted HR, 0.24; 95% CI, -0.07-0.82). However, COL+S6g did not differ in mortality from either COL+SHD or COL for 7-day mortality. At 14 days and 30 days, there were no significant regimens to reduce mortality.

Conclusion: Combining COL+SHD effectively reduced death in 7 days from severe pneumonia in CRAB infection treatment.

Abstract Image

Abstract Image

Abstract Image

粘菌素单药治疗与粘菌素舒巴坦治疗耐碳青霉烯鲍曼不动杆菌肺炎的死亡率:倾向评分分析。
背景:本研究比较了两种不同剂量舒巴坦(每天6克和9-12克)在以粘菌素(COL)为基础的治疗方案和COL单药治疗耐碳青霉烯鲍曼不动杆菌(CRAB)时30天内的死亡率。材料和方法:这项回顾性队列研究纳入了2011年7月1日至2023年4月30日期间在泰国Phramongkutklao医院诊断为因螃蟹感染而严重肺炎的234名参与者。参与者被分为三组:COL单药治疗,COL每日6克舒巴坦(COL+S6g), COL每日9-12克舒巴坦(COL+SHD)。排除肾功能损害患者(血清肌酐≥1.5 mg/dl)后,采用1:2倾向评分(PS)匹配来确保可比较组,以COL组为对照组。匹配变量包括年龄、APACHEⅱ评分、血清肌酐、重症监护病房入住情况和菌血症。各组受试者人数:COL组19人,COL+S6g组32人,COL+SHD组38人。评估的主要结局是7、14和30天的全因死亡率。Kaplan-Meier生存曲线和Log-rank检验用于评估组间差异,多变量Cox回归模型用于确定治疗方案的影响。结果:非匹配PS分析显示,与COL方案相比,COL+SHD方案显著降低死亡率;7天死亡率的风险比(HR)为0.18(95%可信区间[CI], 0.06-0.55), 30天死亡率的风险比为0.53 (95% CI,-0.29-0.97)。此外,COL+SHD方案在7天内的死亡率也比COL+S6g方案更低(HR, 0.29;95% ci, 0.11-0.75)。PS匹配后,与COL方案相比,COL+SHD方案显著降低了7天死亡率(调整HR, 0.24;95% ci, -0.07-0.82)。然而,COL+S6g的死亡率与COL+SHD或COL的7天死亡率没有差异。在第14天和第30天,没有显著降低死亡率的方案。结论:COL+SHD联合治疗可有效降低重症肺炎螃蟹感染患者7天死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Infection and Chemotherapy
Infection and Chemotherapy INFECTIOUS DISEASES-
CiteScore
6.60
自引率
11.90%
发文量
71
审稿时长
22 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信